Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma

Inclusion Criteria: * Pathologically confirmed angioimmunoblastic T-cell lymphoma according World Health Organization (WHO) classification; * Age≥18years; * ECOG≤2; * Patients received at least one systemic treatment previously and achieved no remission or relapsed after first-line treatment; * Adequate bone marrow hematopoietic function: ANC\>1.5 × 109/L，HGB\>90g/L，PLT\>80 × 109/L; * Adequate organ function: ALT≤3 times ULN, TBil≤1.5 times ULN, SCr≥50ml/min/m2, cardiac function grade 0-2 (NYHA); Exclusion Criteria: * Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment; * Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy; * Pregnant or lactating women;